Key Points
- Director Peter Thompson sold 94,583 shares at an average price of $44.54 on Nov. 24, netting about $4.21M and trimming his stake by 2.55% to 3,610,376 shares, per the SEC filing.
- Sionna's stock opened at $43.79 (near its 52-week high of $45), with a market cap of $1.95B and 50/200-day moving averages of $34.04 and $23.96, respectively.
- The company reported quarterly EPS of ($0.46), beating estimates by $0.06, and analysts hold a consensus "Moderate Buy" rating with a $40 average price target amid mixed individual ratings.
Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Peter Thompson sold 1,600 shares of the firm's stock in a transaction that occurred on Wednesday, November 26th. The shares were sold at an average price of $44.49, for a total transaction of $71,184.00. Following the completion of the transaction, the director owned 3,596,886 shares in the company, valued at $160,025,458.14. The trade was a 0.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Sionna Therapeutics Stock Down 1.1%
Shares of Sionna Therapeutics stock traded down $0.49 during trading hours on Thursday, hitting $43.79. The company's stock had a trading volume of 179,798 shares, compared to its average volume of 219,243. Sionna Therapeutics, Inc. has a 1-year low of $7.26 and a 1-year high of $45.00. The business has a fifty day moving average of $34.04 and a 200 day moving average of $23.96. The company has a market capitalization of $1.95 billion and a PE ratio of -8.99.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.06.
Wall Street Analyst Weigh In
SION has been the topic of several recent analyst reports. BTIG Research began coverage on shares of Sionna Therapeutics in a report on Wednesday, November 19th. They issued a "buy" rating and a $50.00 price target on the stock. Jones Trading assumed coverage on Sionna Therapeutics in a report on Monday, September 8th. They issued a "buy" rating and a $46.00 price objective for the company. Royal Bank Of Canada initiated coverage on Sionna Therapeutics in a research report on Wednesday, September 3rd. They set a "sector perform" rating and a $22.00 price target for the company. Weiss Ratings restated a "sell (e+)" rating on shares of Sionna Therapeutics in a research note on Tuesday. Finally, Wall Street Zen downgraded shares of Sionna Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, November 15th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $40.00.
Read Our Latest Report on Sionna Therapeutics
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. acquired a new position in shares of Sionna Therapeutics in the 3rd quarter valued at $30,000. BNP Paribas Financial Markets acquired a new stake in Sionna Therapeutics during the 2nd quarter worth about $31,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Sionna Therapeutics in the second quarter worth about $45,000. Virtus Investment Advisers LLC purchased a new position in shares of Sionna Therapeutics in the second quarter worth approximately $96,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Sionna Therapeutics during the second quarter valued at approximately $117,000.
Sionna Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
